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Stenotrophomonas maltophilia (S. maltophilia) is a globally emerging Gram-negative bacil-
lus that is widely spread in environment and hospital equipment. Recently, the incidence
of infections caused by this organism has increased, particularly in patients with hemato-
logical malignancy and in recipients of hematopoietic stem cell transplantation (HSCT)
having neutropenia, mucositis, diarrhea, central venous catheters or graft versus host
disease and receiving intensive cytotoxic chemotherapy, immunosuppressive therapy,
or broad-spectrum antibiotics. The spectrum of infections in HSCT recipients includes
pneumonia, urinary tract and surgical site infection, peritonitis, bacteremia, septic shock,
and infection of indwelling medical devices. The organism exhibits intrinsic resistance to
many classes of antibiotics including carbapenems, aminoglycosides, most of the third-
generation cephalosporins, and other β-lactams. Despite the increasingly reported drug
resistance, trimethoprim-sulfamethoxazole is still the drug of choice. However, the organ-
ism is still susceptible to ticarcillin-clavulanic acid, tigecycline, fluoroquinolones, polymyxin-
B, and rifampicin. Genetic factors play a significant role not only in evolution of drug resis-
tance but also in virulence of the organism. The outcome of patients having S. maltophilia
infections can be improved by: using various combinations of novel therapeutic agents and
aerosolized aminoglycosides or colistin, prompt administration of in vitro active antibiotics,
removal of possible sources of infection such as infected indwelling intravascular catheters,
and application of strict infection control measures.
Keywords:Stenotrophomonasmaltophilia, bacteremia, neutropenia, hematopoietic stemcell transplantation, drug
resistance
INTRODUCTION
Stenotrophomonas maltophilia (S. maltophilia) is a free living,
motile, aerobic, oxidase negative, glucose non-fermentative Gram-
negative bacillus (GNB). It is frequently isolated from water, soil,
animals, plants, and hospital equipment (1–5). S. maltophilia is
the only species of the genus Stenotrophomonas known to infect
humans. The organism was first isolated from pleural fluid by
Edwards in 1943 and it was called Bacterium brookeri (1, 3). Hugh
and Ryschenkow reclassified Bacterium brookeri as Pseudomonas
maltophilia in 1961. Twenty years later, Swings et al. proposed
reclassification of P. maltophilia as Xanthomonas maltophilia. In
the year 1993, the genus Stenotrophomonas was proposed by
Palleroni and Bradbury, so the organism was finally named as
S. maltophilia (1). Risk factors for S. maltophilia infections in the
general population are very variable and they are listed in Table 1
(1–14).
INFECTIONS CAUSED BY S. MALTOPHILIA
S.maltophilia causes various infectious complications in immuno-
compromised individuals and these include bacteremia, endo-
carditis, respiratory tract infections, meningitis, urinary tract
infections, skin and soft tissue infections, mastoiditis, bone and
joint infections, peritonitis, typhlitis and biliary sepsis, wound
infections, and central venous catheter (CVC)-related infections
(1–3, 5–7, 11, 15–17). Occasionally, distinguishing between col-
onization and infection can be problematic (1–3). S. maltophilia
infections can be complicated by septic shock, respiratory failure,
pulmonary hemorrhage, metastatic cellulitis, tissue necrosis that
may be extensive, septic thrombophlebitis, disseminated infection,
and death (5–8, 11).
S. MALTOPHILIA INFECTIONS IN RECIPIENTS OF HSCT
Recipients of various forms of hematopoietic stem cell trans-
plantation (HSCT) are at risk of a wide range of infectious
complications due to their severely suppressed immunity. Infec-
tions caused by S. maltophilia cause significant morbidity and
mortality in this group of patients (2, 5, 7, 9, 10, 13, 14). Pecu-
liar risk factors predispose recipients of HSCT to S. maltophilia
infections and these are included in Table 2 (2, 5, 7, 9, 10,
13, 14). The most commonly encountered infectious complica-
tions related to S. maltophilia are pneumonia, bacteremia, and
CVC-related infections. S. maltophilia may coexist with other
infections caused by bacterial, viral, fungal, and protozoal agents
(5, 6).
S. maltophilia infections have been described in various forms
of HSCT: autologous transplant and allogeneic, sibling related,
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Table 1 | Risk factors for S. maltophilia infections in the general
population.
(1) Malignancy, particularly hematological malignancy
(2) Human immunodeficiency virus (HIV)
(3) Cystic fibrosis
(4) Intravenous drug abuse
(5) Surgical and accidental trauma
(6) Prolonged hospitalization
(7) Admission to ICU and mechanical ventilation
(8) Indwelling vascular catheters and urinary catheters
(9) Corticosteroids and immunosuppressive therapy
(10) Prior treatment with broad-spectrum antibiotics
(11) Gastrointestinal tract colonization and mucositis
(12) Hematopoietic stem cell transplantation (HSCT)
(13) Travel to hospital by air
ICU, intensive care unit.
Table 2 | Risk factors for S. maltophilia infections in HSCT recipients.
(1) Underlying disease being a hematological malignancy:
leukemia, lymphoma, or multiple myeloma
(2) Cytotoxic chemotherapy
(3) Radiotherapy
(4) Neutropenia and bone marrow aplasia
(5) Graft versus host disease (GVHD)
(6) Immunosuppressive therapies:
corticosteroids and cyclosporine-A
(7) Monoclonal antibodies
(8) Indwelling vascular catheters and urinary catheters
(9) Prior treatment with broad-spectrum antibiotics
(10) Prolonged hospitalization
(11) Admission to ICU and mechanical ventilation
(12) Gastrointestinal tract colonization and diarrhea
(13) Severe mucositis
ICU, intensive care unit.
matched unrelated donor and umbilical cord blood, HSCT (5,
7–9, 13, 14).
CVC INFECTIONS CAUSED BY S. MALTOPHILIA
Central venous catheter-related infections are the most frequent
cause of hospital-acquired bacteremia in critically ill patients. Over
the past two decades, the incidence of CVC-related bacteremia due
to GNB has increased. Among non-fermentative GNB, S. mal-
tophilia is the most frequently isolated pathogen (18). In patients
with cancer, hematological malignancy (HM), and in recipients
of HSCT acquiring bacteremia, CVC-related infection should be
considered seriously as S. maltophilia infections are commonly
associated with the presence of CVCs in these immunocompro-
mised hosts (13,19,20).S.maltophilia CVC-related infections have
also been reported in HSCT recipients. These infections cause bac-
teremia that may be recurrent, may occur as part of polymicrobial
infection, and carry high mortality rates (2, 5, 13, 14).
Indications for removal of CVCs include: (1) bloodstream
infection (BSI) due to GNB particularly multidrug-resistant
(MDR) isolates, (2) critically ill patients such as high risk immuno-
compromised hosts including patients with HM and recipients of
HSCT, and (3) presence of complications such as: severe sepsis
and septic shock, tunnel infection, suppurative thrombophlebitis,
and infective endocarditis (21). Administration of appropriate
antibiotic therapy, immediate removal of infected catheters, and
implementation of strict hand hygiene for health-care personnel
are crucial in the management of CVC-associated infections and
are associated with good prognosis (2, 5, 13, 14, 19, 20).
In patients with documented CVC-related GNB infections,
removal of CVC should be performed within 48–72 h (20, 22).
However, some studies have reported that, even in patients with
long-term CVC having infections caused by GNB, catheter sal-
vage can be achieved in 70% of cases by antimicrobial therapy
and decontamination of the catheter lock with an anti-infective
lock solution (23). Novel securement devices and antibiotic lock
solutions have also been shown to reduce the risk of intravascular
device-related BSIs in prospective randomized trials (24). Other
studies have shown that, despite the use of appropriate antibiotics,
keeping an infected catheter in situ causes not only recurrence in
infection by the same GNB or other micro-organisms but also
death (20, 22). Recurrence of CVC-related infections has been
reported after long latency period reaching 200 days (20).
PNEUMONIA CAUSED BY S. MALTOPHILIA
In hospitalized HSCT recipients, the respiratory tract is the most
common site of isolation of the organism (2, 3). In recipients of
HSCT, the risk factors for hospital-acquired pneumonia due to S.
maltophilia include: (1) immunocompromised health status, (2)
indwelling CVCs, (3) mechanical ventilation, (4) exposure to and
duration of broad-spectrum antibiotic therapy, (5) prolonged hos-
pitalization, (6) admission to an intensive care unit (ICU), and (7)
presence of underlying lung disease such as chronic obstructive
airway disease (25, 26). Treatment of ventilator-associated pneu-
monia (VAP) caused by S. maltophilia includes: (1) high dose
trimethoprim-sulfamethoxazole (TMP-SMZ), which is still con-
sidered the drug of choice based on its excellent in vitro activity,
and (2) an alternative antimicrobial therapy in patients having
drug resistance, allergy, or adverse effects related to TMP-SMZ that
includes a new fluoroquinolone or a combination of doxycycline
and aerosolized colistin (27, 28). Despite the recent improvement
in the short-term prognosis of HSCT recipients transferred to ICU,
S.maltophilia-associated VAP and bacteremia still carry significant
morbidity and mortality (28, 29).
In patients with HM and in recipients of HSCT having severe
lung infection caused by S. maltophilia, life-threatening pul-
monary alveolar hemorrhage (PAH) causing acute respiratory
failure has been reported (7, 8, 30–32). The risk factors for PAH in
these patients include prolonged cytopenias and high C-reactive
protein levels at the onset of BSI or pneumonia (7, 8). However,
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the mechanism of S. maltophilia-induced PAH remains unclear
(7, 8). Despite the expected dismal outcome, prompt institution
of TMP-SMZ in combination with other antimicrobials, provision
of advanced respiratory care, and adequate blood products includ-
ing granulocyte transfusions, if needed, may be life-saving in these
immunocompromised individuals (7, 8, 30–32). In a study that
included 223 recipients of HSCT who had diffuse pulmonary infil-
tration with respiratory compromise: 39% of patients had PAH
and 43% of patients had an organism cultured from BAL. Patient
who had PAH and an organism isolated from BAL had the worst
outcome and isolation of a microbial organism from BAL was a
strong predictor of poor prognosis (31).
BACTEREMIA CAUSED BY S. MALTOPHILIA
S. maltophilia bacteremia is hospital-acquired in 76% of patients
and has been reported in up to 24% of recipients of allogeneic
HSCT (9, 18). The risk factors for S. maltophilia bacteremia are
included in Table 3 (5, 6, 9, 12, 14, 18, 19, 33–36). The sources
of infection in patients having S. maltophilia bacteremia include:
primary bacteremia with no known source, CVC-associated infec-
tions, respiratory tract infections such as pneumonia in mechan-
ically ventilated patients, gastrointestinal tract (GIT) infections,
and faulty replacement of hand washing soap (5, 6, 9, 10, 14).
Outbreaks of S. maltophilia bacteremia have been described in
recipients of allogeneic HSCT having neutropenia and mechanical
ventilation (9, 10). These outbreaks were attributed to: (1) hospital
equipments acting as reservoirs for S. maltophilia, (2) prevalence
of GIT colonization with the organism in patients who develop
invasive infections, (3) selective pressure of antimicrobial therapy,
and (4) faulty replacement of hand washing soap (9, 10).
The overall mortality related to S. maltophilia bacteremia may
reach 33% (5, 18). Studies have also shown that 14-day and
30-day mortality rates in patients having S. maltophilia BSIs
are 24 and 35%, respectively (6, 37). The 30-day mortality rate
related to S. maltophilia bacteremia is higher and has worse
Table 3 | Risk factors for S. maltophilia bacteremia.
(1) CVC infection
(2) Prolonged hospitalization
(3) Admission to ICU and mechanical ventilation
(4) Prior treatment with broad-spectrum antibiotics
(5) Severe neutropenia
(6) Corticosteroid treatment
(7) Underlying disease being a hematological malignancy
(8) Aggressive cytotoxic chemotherapy
(9) Immunosuppressive therapy
(10) Major trauma or recent surgical intervention
(11) Severe mucositis
(12) Total parenteral nutrition
ICU, intensive care unit; CVC, central venous catheter.
prognosis compared with bacteremia related to other glucose non-
fermenting GNB such as Pseudomonas aeruginosa andAcinetobac-
ter species (37). Factors independently associated with mortality
in patients having S. maltophilia bacteremia include: (1) profound
neutropenia, (2) thrombocytopenia, (3) septic shock or hypoten-
sion at the onset of bacteremia, (4) inappropriate antimicrobial
therapy, and (5) having high sepsis-related organ failure assess-
ment index (6, 14, 18). In patients having S. maltophilia BSIs, good
prognosis is associated with early administration of appropriate
antimicrobial therapy, removal of infected CVCs, recovery of bone
marrow function, and taking enough preventive and isolation
measures (5, 14, 35, 36).
ANTIMICROBIAL SUSCEPTIBILITY AND THERAPEUTIC
OPTIONS
S. maltophilia has been shown to be susceptible to the fol-
lowing antibiotics: (1) TMP-SMZ, (2) ticarcillin-clavulanate, (3)
piperacillin-tazobactam, (4) cephalosporins such as ceftazidime,
(5) aminoglycosides such as streptomycin and amikacin, (6) tetra-
cyclines such as minocycline, doxycycline, and tigecycline, (7) flu-
oroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin,
gatifloxacin, and trovafloxacin, (8) polymyxins such as colistin sul-
fate, and (9) other antibiotics such as rifampicin, chloramphenicol,
salbactam-cefoperazone, moxalactam as well as silver sulfadiazine
(1, 3, 5–7, 10, 11, 14, 15, 38–48).
The organism has been reported to be resistant to the fol-
lowing antimicrobials: (1) carbapenems such as imipenem and
meropenem, (2) amoxicillin-clavulanic acid, (3) aminoglyco-
sides such as tobramycin and gentamicin, (4) most of the
cephalosporins such as cefpirome and cefsulodin, (5) quinolones
and most of the anti-pseudomonal penicillins. Also, some strains
have been reported to be resistant to tetracyclines, ciprofloxacin,
chloramphenicol (1, 5, 10, 11, 16, 39, 49–51).
In a large survey (CANWARD 2007-11 Study) performed in
Canada between 2007 and 2001 that included 22,746 clinical iso-
lates from hospitals in 8 districts: S. maltophilia accounted for
1.4% of all isolates and the organism ranked number 16 among
the 20 most common pathogens isolated from Canadian hospitals
(42). Also, in a 6-month prospective multicenter study performed
in 9 teaching hospitals in France that included 158 patients, S.
maltophilia was the most common non-fermentative GNB (39%)
isolated from hospitalized patients (52). In the former study, tige-
cycline displayed good in vitro activity against MDR isolates of
S. maltophilia and in the latter study the high incidence of MDR
among S. maltophilia isolates rendered empirical antimicrobial
therapy inappropriate (42, 52).
Various studies have shown synergistic activity when the
following combinations are used: TMP-SMZ and ticarcillin-
clavulanate, TMP-SMZ and ceftazidime, ticarcillin-clavulanate
and levofloxacin, ticarcillin-clavulanate and aztreonam as well as
ceftazidime and ciprofloxacin (43–45). Only one study showed
that TMP-SMZ and fluoroquinolones are equally effective once
used as monotherapies in treating S. maltophilia-related infec-
tions (53). MDR isolates of S. maltophilia have shown excellent
responses to combinations of new fluoroquinolones and tetracy-
cline derivatives (46). Future therapies that have the potential to
slow the development of drug resistance include phage therapy,
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nanoemulsions, use of antisense RNA to target genes involved in
virulence, and use of adjuvants that restore antibiotic efficacy (43).
Studies on in vitro susceptibility of S. maltophilia performed
in several countries have shown variable results (42, 47, 48, 52–
56). A Greek 6-year survey showed that in vitro susceptibility of S.
maltophilia to TMP-SMZ, colistin, netlimicin, and ciprofloxacin
were 85.3, 91.2, 85.3, and 82.4%, respectively (47). A Spanish sur-
vey showed: (1) S. maltophilia was found to be highly resistant to
several antibiotics, and (2) TMP-SMZ and ticarcillin-clavulanate
were the only antimicrobials that exhibited good in vitro activ-
ity against S. maltophilia (48). One Korean study showed that
susceptibility rates of S. maltophilia to TMP-SMZ, minocycline,
and levofloxacin were 96, 99, and 64% respectively (54). Another
Korean survey showed: (1) the degree of antimicrobial resistance,
even to TMP-SMZ, varied considerably between isolates, and
(2) accurate identification was essential for appropriate selection
of treatment options and alternative therapies in case of TMP-
SMZ resistance (55). Finally, a study performed in Saudi Arabia
showed that in vitro resistance rates of S. maltophilia to various
antibiotics were as follows: imipenem 100%, gentamicin 87.4%,
aztreonam 86%, ciprofloxacin 77%, piperacillin–tazobactam 61%,
ceftazidime 57%, and TMP-SMZ 9.5% (56).
DRUG RESISTANCE IN S. MALTOPHILIA
Unfortunately, the organism is resistant to several antimicrobials
and there is a growing concern about the magnitude of drug resis-
tance displayed by S. maltophilia (2–4, 17, 40, 51, 57–63). There
are several mechanisms of drug resistance and these are listed in
Table 4. Genetic determinants of drug resistance in S. maltophilia
include class 1 integrons carrying sul1 gene and insertion sequence
Table 4 | Mechanisms of S. maltophilia drug resistance.
Mechanism Examples
(1) Modification of outer membrane
proteins
• Protein expression
• Reduction in permeability
(2) Expression of chromosomally
encoded multidrug efflux pumps
• Sme ABC
• Sme DEF
• Cadmium efflux determinants:
Cad A and Cad C
• Resistance-nodulation cell
division (RND) efflux pump.
(3) Enzyamatic mechanisms • Expression of chromosomal or
plasmid encoded β-lactamases
such as L1 and L2 β-lactamases
• Aminoglycoside acetylcholine
modifying enzyme a (6′) Iz gene.
• Inactivation of macrolide
phosphotransferase.
(4) Target site alterations • Phosphoglucomutase gene
mutations on liposaccharide.
•Mutations of bacterial
topoisomerase and gyrase
genes.
common region (ISCR) elements carrying sul2 gene (Table 5) (2–
4, 17, 40, 51, 57–63). The mechanisms of drug resistance vary
from one antimicrobial to another and at times each antibiotic
may have different enzymes or genes involved in the evolution
of its drug resistance. For example: class 1 integrons (sul1) and
ISCR elements (sul 2) are involved in the resistance to TMP-SMZ,
sme DEF, and smQnr are involved in quinolone resistance and
three different mechanisms, aac (6′) Iz acetyl transferase modi-
fying enzyme, efflux pumps, and outer membrane modifications,
are involved in drug resistance to aminoglycosides (Tables 4 and
5) (51, 57, 58, 62).
Several molecular mechanisms contribute to MDR and they
include plasmids, integrons, and transposons (2). Resistance of
S. maltophilia is mediated by a relatively impermeable cell mem-
brane, the production of β-lactamases (L1 and L2), and an efficient
resistance nodulation cell division (RND) efflux pump Sme DEF
able to extrude fluoroquinolones, chloramphenicol, and tetracy-
cline (64). Biofilm formation leads to colonization of mucosal
surfaces, wounds, fluids, catheters, and implants and this con-
tributes to persistence of the organism (2, 65, 66). Persistence of
S. maltophilia, virulence of the bacterium, and inappropriate use
of broad-spectrum antibiotics predispose to drug resistance (2).
Table 5 | Genetic determinants of drug resistance.
Genetic determinant Antibiotics involved in drug resistance
Sul 1 and Sul 2 Trimethoprim–sulfamethoxazole
Sm Qnr R Quinolones, tetracyclines.
ISCR Trimethoprim–sulfamethoxazole, quinolones,
aminoglycosides, β-lactams
Sme ABC Quinolones such as ciprofloxacin,
aminologycosides, β-lactams
Sme DEF • Quinolones such as ciprofloxacin and
ofloxacin
•Macrolides
• Chloramphenicol
•Tetracycline
• Novobiocin
Sme IJK • Quinolones such as ciprofloxacin and
levofloxacin
• Aminoglycosides
•Tetracyclines
Sme OP and Tol C sm • Aminoglycosides such as gentamicin and
amikacin
•Trimethoprim-sulfamethoxazole
• Nalidixic acid
• Chloramphenicol
• Erythromycin and other macrolides
• Doxycycline
• Leucomycin
• Chemicals such as
tetrachlorosalicylanilide.
Sme Z • Aminoglycosides
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Studies have shown that genetic factors play a major role in
drug resistance (2, 67). The wide range of antimicrobial drug
resistance genes and mobile genetic elements found suggests that
S. maltophilia can act as a reservoir of antimicrobial drug resis-
tance determinants in a clinical environment, which is an issue of
considerable concern (67). The genome sequence of S. maltophilia
reveals its capacity for environmental adaptation that presumably
contributes to its persistence in vivo (67). The genome sequencing
of S. maltophilia isolates K 279a and AU 12-09 revealed huge num-
ber of genes coding for MDR to several antimicrobials (67, 68).
Although it is not a highly virulent organism, the large number
of genes involved, the MDR phenotype, and its ability to attach
to mucosal surfaces and surfaces of hospital equipment make the
organism more persistent and more difficult to eradicate (67).
S. maltophilia has high intrinsic resistance to a variety of
structurally unrelated antimicrobials including aminoglycosides,
quinolones, and β-lactams. Multidrug efflux transport systems are
an important mechanism for bacteria to combat antimicrobial
agents. Among efflux transport systems, the RND-type multidrug
efflux systems play a critical role in MDR, particularly in GNB
(69). Two efflux systems have been identified in S. maltophilia,
Sme ABC and Sme DEF. Genome sequence analysis has revealed
that S. maltophilia K279a encodes many putative RND efflux sys-
tems including Sme ABC, Sme DEF, Sme GH, Sme IJK, Sme MN,
Sme OP, Sme VWX, and Sme YZ. Sme U1–V–W–U2–Y, which is
a novel RND-type efflux pump operon, composed of five genes,
has been characterized (69). The SmQnr protein encoded by the
chromosome qnr determinant of S. maltophilia has been shown to
contribute to the intrinsic quinolone resistance of S. maltophilia.
Inactivation of SmqnrR contributes to an acquired increase in
quinolone and tetracycline minimum inhibitory concentrations
(MICs) for S. maltophilia (Table 5) (70).
A five-gene cluster (tolCsm, Sme RO, Sme D, Sme P, and pcm)
of S. maltophilia was characterized (71). The pcm-tolCsm makes
a significant contribution to multidrug resistance of S. maltophilia
(72). Deletion of tolCsm increases susceptibility of S. maltophilia
KJ2 to: (1) several antimicrobial agents including aminoglyco-
sides, macrolides, doxycycline, nalidixic acid, chloramphenicol,
and TMP-SMZ, and (2) chemical compounds including car-
bonylcyanide 3- chlorophenyl hydrazine, tetrachlorosalicylanilide,
fusidic acid, paraquat, crystal violet, menadine, and plumbagin
(72). The sul1 and sul 2 genes lead to a high rate of TMP-SMZ
resistance (Table 5) (73). ISCR elements are associated with a
variety of antibiotic resistance genes. At least 13 ISCRs have been
identified and they are associated with resistance to TMP-SMZ,
quinolones, aminoglycosides, and β-lactams (74).
The increasing number of S. maltophilia isolates seen in ICUs,
their resistance to mainstay antibiotics, their genetically diverse
nature and possible cross-transmission within hospitals strongly
underscore the need for continuous surveillance for S. maltophilia
in hospital settings (75). Environmental isolates of S. maltophilia
have been found to have lower overall mutation frequencies com-
pared with clinical isolates (76). Trichloroethylene (TCE) is one of
the major ground water pollutants throughout the world (77). S.
maltophilia PM102 is capable of growth on TCE as the sole carbon
source and has the capacity to degrade TCE efficiently (77, 78). S.
maltophilia PM102 has been identified by 16S rDNA sequencing
and has been characterized by Fourier transform infrared spec-
troscopy (FT-IR) (78, 79). Triclosan is one of the most widely
used biocides. Binding of triclosan to Sme T induces antibiotic
resistance in S. maltophilia. Triclosan is a good inducer of the
expression of MDR efflux pump Sme DEF and exposure of S.
maltophilia to triclosan selects for antibiotic resistance (80).
NEW DIAGNOSTIC METHODS
As infections caused by S. maltophilia are associated with con-
siderable morbidity and mortality and as the organism has the
potential to acquire resistance to many classes of antimicrobials, it
is essential to make diagnosis and identification of the organism as
early as possible in order to institute appropriate antibiotic therapy
promptly. This can be achieved by utilizing the new or advanced
laboratory and radiological diagnostic tools (81).
MOLECULAR DIAGNOSTICS IN S. MALTOPHILIA INFECTIONS
Detection of S. maltophilia in blood cultures can be achieved more
rapidly by combining flow cytometry and fluorescence in situ
hybridization compared to standard detection methods (81). Both
conventional and real-time polymerase chain reaction (PCR) are
sensitive methods for diagnosing GNB infections including those
caused by S.maltophilia in cancer patients having febrile neutrope-
nia. Although PCR is more costly than routine blood cultures, its
use in patients with HM having febrile neutropenia can be justified
as studies have shown that the use of PCR under such circum-
stances has improved the outcome and has reduced the mortality
related to these serious infections (81–83).
Early identification of pathogens and antimicrobial resistance
in BSIs decreases morbidity and mortality in patients with HM
and in recipients of HSCT (83–85). Molecular techniques, such as
PCR, ribosomal RNA, and nucleic acid amplification, can augment
cultural methods in the diagnosis of causal agents of bacteremia
in these patients so that appropriate antimicrobial therapies can
be commenced particularly in culture-negative infection episodes
(83, 85). Although blood cultures remain the gold standard for
detecting BSIs, real-time PCR is a valuable complementary tool
in the management of BSIs in recipients of HSCT, thus allow-
ing early identification of pathogens and antimicrobial resistance
genes (84).
The LightCycler SeptiFast assay, a multiple blood PCR tech-
nique, when combined with blood cultures provides clinically
relevant information for the diagnosis of blood culture-negative
febrile neutropenia in patients with persistent fever despite
antibacterial therapy or when a non-responding bacterial infec-
tion or an invasive fungal infection is suspected (86, 87). Results
of the SeptiFast assay may lead to a more targeted antimicrobial
treatment early after the onset of fever (88).
DIAGNOSTICS IN PULMONARY COMPLICATIONS OF S. MALTOPHILIA
In patients with febrile neutropenia, computed axial tomography
(CAT) scan of the thorax is more sensitive than chest X-ray (CXR)
in detecting pulmonary infections (89). Positron emission tomog-
raphy scans are also valuable in defining the extent of infection and
guiding management in immunocompromised individuals having
febrile neutropenia (90).
In febrile neutropenic patients, having a normal CXR does not
rule out pneumonia. High resolution CAT (HR-CAT) scans can
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detect pneumonia 5 days earlier than CXR (91, 92). Therefore,
patients with febrile neutropenia with no evidence of pneumonia
on CXR should have HR-CAT scans (91, 92). The most common
HR-CAT scan findings in recipients of HSCT having pneumonia
are air-space consolidation, micronodular shadows, and ground-
glass opacities involving middle and lower lung fields (93). A study
that included 112 patients with HM and recipients of HSCT hav-
ing febrile neutropenia showed the following results: sensitivity
of HR-CAT scans in detecting pneumonia in patients with febrile
neutropenia and in recipients of HSCT was 87 and 88%, specificity
was 57 and 67%, respectively, while negative predictive values were
88 and 97%, respectively (92).
Fiber-optic bronchoscopy and bronchoalveolar lavage (BAL)
have generally been considered as safe and accurate procedures for
evaluation of patients having pulmonary infiltrates (94–96). The
diagnostic yield of bronchoscopy in HSCT recipients may reach
75% and the results of BAL may change treatment in up to 51%
of episodes of pneumonia (94–96).
Lung biopsies carry significant risk of morbidity and mortal-
ity in recipients of HSCT who are fragile, thrombocytopenic, and
immunocompromised (94). Patients with HM and recipients of
HSCT having pulmonary infiltrates or nodular lung lesions are
at risk of treatment failure once conventional broad-spectrum
antimicrobial therapies are used on empirical basis as filamen-
tous fungi and MDR-GNB such as Pseudomonas aeruginosa and S.
maltophilia may be involved etiologically (97). In these patients,
pulmonary lesions should be characterized by HR-CAT scans,
bronchoscopy, BAL, and even lung biopsies, if absolutely indi-
cated (98). The choice of optimal biopsy should be individualized
and guided by several patient and institutional factors. It is highly
recommended to adopt interdisciplinary approach in order to
optimize diagnosis and treatment (98).
In patients with HM and in recipients of HSCT, molecular
diagnostic techniques such as PCR and nucleic acid amplification
are promising tool for the rapid etiological diagnosis of pneu-
monia (99, 100). Their usefulness in the early diagnosis of viral
and atypical pneumonia is well documented. However, their role
in early detection of bacterial causes of pneumonia in patients
with HM and in recipients of HSCT needs further evaluation and
standardization of the diagnostic tools utilized (99, 100).
TREATMENT OF S. MALTOPHILIA INFECTIONS
Trimethoprim-sulfamethoxazole is still the drug of choice for
S. maltophilia infections (Table 6) (4, 5, 14, 16, 67, 101, 102).
Unfortunately, resistance to TMP-SMZ is increasingly reported
and the rate of resistance is 8.3–9.1% (4, 16, 34, 36, 101, 102).
However, for successful eradication of S. maltophilia infections,
TMP-SMZ must be given in a sufficient dose and at a proper fre-
quency in order to produce adequate concentrations at the site(s)
of infection. Determination of the appropriate dosing regimen
requires optimum knowledge and utilization of the pharmaco-
kinetics and pharmacodynamics of TMP-SMZ (103). Currently,
the most effective antibiotics against S. maltophilia are: TMP-
SMZ, ticarcillin-clavulanic acid, minocycline, and the new fluo-
roquinolones such as moxifloxacin, ofloxacin, and levofloxacin.
These agents can be used either alone or in various combinations
(36, 64).
Table 6 |This shows available and future therapeutic modalities for
S. maltophilia infections.
Therapeutic modality Examples and details
Monotherapies •TMP-SMZ: still the drug of choice
• Fluoroquinolones: ciprofloxacin, levofloxacin,
moxifloxacin, gatifloxacin, trovafloxacin,
ofloxacin.
•Ticarcillin-clavulanate
•Tetracyclines: minocycline, tigecycline
• Cephalosporines: ceftazidime.
Combination therapies •TMP-SMZ and ticarcillin-clavulanate
•TMP-SMZ and ceftazidime
•TMP-SMZ and tigecycline
•Tigecycline and amikacin
• Colistin and tigecycline
• Aerosolized colistin and doxycycline
•MDR species: colistin and rifampicin or
colistin and TMP-SMZ
Targeted and future
therapies
• Inhibitors of efflux pumps
• Inhibitors of β-lactamases
• Antimicrobial peptides
• Cationic compounds
• Bacteriophages
• Nanoemulsions
•Telavancin and colistin
• Plant oils and constituents of green tea
TMP-SMZ, trimethoprim-sulfamethoxazole; MDR, multidrug resistance.
Alternative therapies to TMP-SMZ include: (1) monotherapies
including cephalosporins such as ceftazidime; fluoroquinolones
such as ciprofloxacin, levofloxacin including the aerosolized
form, moxifloxacin, gatifloxacin, and trovafloxacin; ticarcillin-
clavulanate and tetracyclines such as tigecycline or minocycline
and (2) drug combinations such as: TMP-SMZ and ticarcillin-
clavulanate, TMP-SMZ and tigecycline, tigecycline and amikacin,
colistin and tigecycline, telavancin and colistin, or aerosolized col-
istin and doxycycline (Table 6) (2, 4, 17, 101, 104, 105). Several
recent studies have shown the efficacy of levofloxacin monother-
apy as an alternative to treatment with TMP-SMZ (37, 53, 106).
Antimicrobials that are active against S. maltophilia should prefer-
ably be used in combinations, particularly once MDR S. mal-
tophilia is isolated (42–48). In the treatment of infections caused
by MDR S. maltophilia, colistin can be used in combination with
rifampicin or TMP-SMZ (107).
The Fourth European Conference on Infections in Leukemia
(ECIL-4, 2011) recommended the following targeted therapies
for S. maltophilia infections in patients with leukemia and in
recipients of HSCT: (1) TMP-SMZ, (2) fluoroquinolones such
as ciprofloxacin and moxifloxacin, (3) ticarcillin-clavulanate, and
(4) in seriously ill or neutropenic patients, combination therapy
may be considered such as TMP-SMZ and ceftazidime or TMP-
SMZ and ticarcillin-clavulanate (41). Targeted therapy against
MDR bacteria should be based on: (1) in vitro susceptibil-
ity data, (2) knowledge of the best treatment option against
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the particular species or phenotype of bacteria, (3) pharma-
cokinetic and pharmacodynamic data, and (4) careful assess-
ment of risk–benefit balance (41). For infections due to GNB,
antimicrobials should be preferably used in combination with
other agents that remain active in vitro because of suboptimal
efficacy in case of tigecycline and the risk of emergent resis-
tance in case of fosfomycin. There is a growing problem of
antimicrobial resistance among pathogens isolated from patients
with HM and recipients of HSCT in many centers and this
increasingly influences the choice of empirical antimicrobial
therapy (41).
The standard therapy with TMP-SMZ may be difficult to
administer in recipients of HSCT particularly those having cytope-
nias due to its myelosuppressive effects (14). In such patients, the
following alternative antimicrobials can be used alone or in com-
binations: ceftazidime or ceftriaxone, ticarcillin-clavulanic acid,
and levofloxacin or moxifloxacin (5, 14). An additional con-
cern is that these patients receive plenty of other drugs such as
cyclosporine-A, mycophenolate mofetil, triazoles, and antivirals
that may predispose not only to more adverse effects but also to
drug interactions (41). Therefore, use of specific antimicrobials
should be cautiously considered. Antimicrobial stewardship aim-
ing to minimize unnecessary broad-spectrum antibiotic use and
its associated collateral damage and resistance selection is crucial
in the current era of growing drug resistance (41). In patients with
HM and in recipients of HSCT having infections caused by MDR
S. maltophilia, IV colistin with dosage adjusted to renal function is
relatively safe, even if given concomitantly with other nephrotoxic
medications (108).
In patients with device-associated infections caused by S. mal-
tophilia, fluoroquinolones particularly levofloxacin can be used to
eradicate such infections once used in combination with other
antimicrobials (109). In patients with VAP caused by MDR S.
maltophilia, the following treatment options are safe and effica-
cious: (1) doxycycline and aerosolized colistin, and (2) IV colistin
(27, 110, 111). Despite the emergence of antimicrobial resistance,
fluoroquinolone prophylaxis may be considered as an appealing
option in recipients of HSCT. However, their usefulness in pro-
phylaxis in allogeneic HSCT should be evaluated in randomized
trials (112, 113).
NEW AND FUTURE THERAPEUTIC MODALITIES
New therapeutic strategies and future targeted therapies for S.
maltophilia infections include the use of antimicrobial peptides,
cationic compounds, bacteriophages, nanoemulsions, plant oils,
constituents of green tea as well as inhibitors of β-lactamases and
efflux pumps (2, 17).
The targeted therapies include bacterial efflux pumps inhibitors
(BEPIs), inhibitors of β-lactamases, inhibitors of bacterial quo-
rum sensing, antimicrobial peptides, bioengineered bacteriophage
therapy, monoclonal antibodies directed against S. maltophilia,
and antibodies to surface polysaccharides, which mediate biofilm
formation and that are expressed during infection (Table 6)
(114–124). Several families of BEPIs have been described (116).
BEPIs have variable mechanisms of actions that include increas-
ing intracellular concentrations of antibiotics that are expelled by
efflux pumps, restoration of drug susceptibility of resistant clinical
isolates, reduction of capability of acquired additional resistance,
and reduction of intrinsic bacterial resistance to antimicrobials
(114–116).
PREVENTION OF S. MALTOPHILIA INFECTIONS
Prevention of S. maltophilia infections can be achieved by: (1)
health education of health-care personnel to prevent transmis-
sion and spread of this opportunistic pathogen, (2) observation
of aqueous-associated environment and regular cleaning and dis-
infection of surfaces of medical instruments, (3) reinforcement of
hand washing hygiene, (4) avoidance of using hospital tap water
for bathing or cleaning of wounds, (5) discarding residual antibi-
otic solutions and contaminated fluids, (6) regular maintenance of
hospital equipment and replacement of defective and worn parts,
and (7) control of antimicrobial consumption (2, 17). Limita-
tion of antimicrobial resistance and restriction of spread of the
organism can be achieved by: appropriate antimicrobial selection,
surveillance systems, and effective infection control measures (28).
COURSE AND PROGNOSIS OF S. MALTOPHILIA INFECTIONS
Morbidity and mortality associated with severe S. maltophilia
infections are high due to the following reasons: (1) the organism
is inherently resistant to antimicrobials, (2) antimicrobial resis-
tance increases when the patient is colonized with the organism or
given broad-spectrum antibiotics, and (3) the debilitated status of
individuals acquiring the infection (6).
Risk factors for S. maltophilia infection-associated mortal-
ity include: (1) severely immunocompromised hosts, particularly
those with underlying HM and recipients of HSCT, (2) septic
shock, (3) organ failure, (4) bacteremia, (5) lung involvement
such as pneumonia or pulmonary hemorrhage, (6) extensively
drug-resistant organism, (7) exposure to carbapenems, (8) throm-
bocytopenia, and (9) high acute physiology and chronic health
evaluation (APACHE) score in patients admitted to the ICU (2, 5,
7–9, 18, 60, 125, 126).
In S. maltophilia-associated infections, successful outcome is
associated with administration of antibiotics to which the organ-
ism is susceptible, removal of infected devices such as CVCs,
recovery of bone marrow function, taking enough preventive and
isolation measures, and having a high index of suspicion (2, 8).
CONCLUSION
Stenotrophomonas maltophilia is a globally emerging pathogen
that causes serious infectious complications in immunocompro-
mised patients in particular. It also exhibits a wide range of drug
resistance mechanisms and this complicates the management of
infections caused by this GNB. It is essential to utilize the avail-
able antimicrobials appropriately, use novel agents to which the
organism is susceptible, and to strictly apply infection control mea-
sures in order to decrease the incidence of infections caused by S.
maltophilia.
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